Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review

被引：53

作者：

Al Ustwani, Omar ^{[1
]}

Lohr, James ^{[1
]}

Dy, Grace ^{[1
]}

Levea, Charles ^{[2
]}

Connolly, Gregory ^{[3
]}

Arora, Pradeep ^{[1
]}

Iyer, Renuka ^{[1
]}

机构：

[1] Roswell Pk Canc Inst, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA

[2] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA

[3] Univ Rochester, Dept Med, Rochester, NY 14627 USA

来源：

JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2014年 / 5卷 / 01期

关键词：

D O I：

10.3978/j.issn.2078-6891.2013.042

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E30 / E33

页数：4

共 16 条

[1]

[Anonymous], P T, V36, P48

[2] Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome [J].

Ariceta, Gema ;

Besbas, Nesrin ;

Johnson, Sally ;

Karpman, Diana ;

Landau, Daniel ;

Licht, Christoph ;

Loirat, Chantal ;

Pecoraro, Carmine ;

Taylor, C. Mark ;

Van de Kar, Nicole ;

VandeWalle, Johan ;

Zimmerhackl, Lothar B. .

PEDIATRIC NEPHROLOGY, 2009, 24 (04) :687-696

[3] Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report [J].

Bharthuar, Anubha ;

Egloff, Lori ;

Becker, Joanne ;

George, Marina ;

Lohr, James W. ;

Deeb, George ;

Iyer, Renuka V. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) :177-181

[4] Gemcitabine-induced hemolytic uremic syndrome: a case report [J].

Brodowicz, T ;

Breiteneder, S ;

Wiltschke, C ;

Zielinski, CC .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (24) :1895-1896

[5] Genetics of HUS:: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome [J].

Caprioli, Jessica ;

Noris, Marina ;

Brioschi, Simona ;

Pianetti, Gaia ;

Castelletti, Federica ;

Bettinaglio, Paola ;

Mele, Caterina ;

Bresin, Elena ;

Cassis, Linda ;

Gamba, Sara ;

Porrati, Francesca ;

Bucchioni, Sara ;

Monteferrante, Giuseppe ;

Fang, Celia J. ;

Liszewski, M. K. ;

Kavanagh, David ;

Atkinson, John P. ;

Remuzzi, Giuseppe .

BLOOD, 2006, 108 (04) :1267-1279

[6] PHASE-II TRIAL OF GEMCITABINE (2,2'-DIFLUORODEOXYCYTIDINE) IN PATIENTS WITH ADENOCARCINOMA OF THE PANCREAS [J].

CASPER, ES ;

GREEN, MR ;

KELSEN, DP ;

HEELAN, RT ;

BROWN, TD ;

FLOMBAUM, CD ;

TROCHANOWSKI, B ;

TARASSOFF, PG .

INVESTIGATIONAL NEW DRUGS, 1994, 12 (01) :29-34

[7] Hemolytic uremic syndrome as a complication of gemcitabine treatment:: report of six cases and review of the literature [J].

Desramé, J ;

Duvic, C ;

Bredin, C ;

Béchade, D ;

Artru, P ;

Brézault, C ;

Defuentes, G ;

Poirier, JM ;

Dourthe, LM ;

Coutant, G ;

Chaussade, S ;

de Gramont, A ;

Algayres, JP .

REVUE DE MEDECINE INTERNE, 2005, 26 (03) :179-188

[8]

Fung MC, 1999, CANCER-AM CANCER SOC, V85, P2023

[9]

Glezerman I, 2009, CLIN NEPHROL, V71, P130

[10] Is Therapeutic Plasma Exchange Indicated for Patients with Gemcitabine-Induced Hemolytic Uremic Syndrome? [J].

Gore, Ethan McCaleb ;

Jones, Benjamin Scott ;

Marques, Marisa B. .

JOURNAL OF CLINICAL APHERESIS, 2009, 24 (05) :209-214

← 1 2 →